Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Cytokine Release Syndrome (CRS) is acute systemic inflammation associated with treatments from therapeutic antibodies, CAR-T cell therapy, and even haploidentical marrow transplantations. During CRS, a large number of cytokines are rapidly released into the bloodstream from immune cells affected by the immunotherapy. Symptoms may range from headache and fever to organ damage or even death. The Human Cytokine Antibody Arrays facilitate study of the cytokine network by allowing you to monitor the relative abundance of certain human cytokines from a variety of sources in a high-throughput manner.
Creative Biolabs'human antibody arrays platform bring cytokine detection to a new level. With this system, you can rapidly and accurately profile the expression of multiple cytokines–at the protein level–in the range of picogram per mL. Use the human antibody arrays to determine human cytokine content in serum, plasma, and conditioned media.
The human cytokine antibody arrays are based on the sandwich ELISA method for detecting protein. First, a capture antibody specific to a particular cytokine protein is immobilized on the array membrane. Second, sample is incubated with the capture antibody, proteins are given time to bind, and any unbound protein is washed away. Then, a second antibody, known as the detection antibody, is introduced. This biotin-conjugated antibody binds to a second epitope on the protein, creating an antibody "sandwich" around the cytokine. Through a biotin-strepavidin interaction, an enzyme is used to visualize the bound cytokine protein. The linkage between capture antibody, target protein, and detection antibody offers a high degree of selectivity and sensitivity.
Fig.1 Schematic flow chart of the Human Antibody Array assay.
The human cytokine antibody array provides researchers an easy-to-use and cost-effective means of generating a cytokine profile for each sample. Our high-quality reagents help ensure the accuracy of your results. Each kit is manufactured in our ISO13485 registered facility.
If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
